Sobi launches new haemophilia treatment in UK
pharmafile | January 19, 2016 | News story | Manufacturing and Production, Sales and Marketing | elocta, haemophilia a, sobi
Swedish Orphan Biovitrum Ltd (Sobi) has launched its haemophilia A treatment Elocta (efmoroctocog alfa) in the UK, following its EU marketing authorisation in December 2015.
Elocta is a recombinant human factor VIII Fc fusion protein with an extended half-life, and is the first haemophilia A treatment in the EU to offer prolonged protection against bleeding episodes with prophylactic injections every three to five days.
Elocta is indicated for both preventative and on-demand treatment of bleeding in people with haemophilia A and can be used for all age groups. The recommended prophylactic dose of Elocta is 50 international units (IU) per kilogram every three to five days, although the dose may be tailored by the individual’s doctor between 25 to 65 IU/kg depending on the severity of the factor VIII deficiency, the location and frequency of bleeding, and the patient’s activity level and overall health.
“The launch of Elocta is an important milestone for the haemophilia community in the UK, offering people with haemophilia A a treatment option that provides extended protection against bleeds,” says Neil Dugdale, general manager UK at Sobi.
“Since the approval of Elocta in the EU, our focus has been to ensure timely and sustainable access to Elocta for people living with haemophilia A in the UK. Whilst we await the potential inclusion of Elocta within a National Framework agreement by mid-year, we are delighted to be able to announce that the Elocta is now available for sale via our distributor Alloga UK.”
Joel Levy
Related Content
Sobi’s Aspaveli receives European Commission approval for treatment of two rare kidney diseases
Sobi has announced that its Aspaveli (pegcetacoplan) has received approval from the European Commission (EC) …
Mavatar announces research collaboration with Sobi
Mavatar has announced the initiation of a non-clinical research collaboration with Sobi, using Mavatar’s technology …
FDA approves Gamifant for macrophage activation syndrome in Still’s disease
The US Food and Drug Administration (FDA) has approved Gamifant (emapalumab-lzsg) for the treatment of …
